Swiss drugs group Novartis said Tuesday it’s recently acquired U.S. vaccine firm ImmTech Biologics has won a
conditional license in the United States to use Treponema Bacterin, a vaccine designed to prevent digital dermatitis — hairy heel warts — in dairy cattle.

“Digital dermatitis is a costly disease for dairy producers and Treponema Bacterin is the only immunological solution available,” said Mark Hodgson, President of Novartis Animal Vaccines Inc., in a statement.
“It allows dairy producers to reduce environmental, worker safety and milk-quality issues associated with chemical and antibiotic management of heel warts,” he added.